Results 211 to 220 of about 78,948 (301)

Inflammatory and Immunological Basis of Periodontal Diseases

open access: yesJournal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima   +3 more
wiley   +1 more source

Changes in circulating NK and innate-like T cells in type 1 and type 2 diabetes. [PDF]

open access: yesFront Immunol
Loguinova M   +13 more
europepmc   +1 more source

Development of Single-Molecule Enzyme Activity Assay for Serine Hydrolases Using Activity-Based Protein Labeling Probes. [PDF]

open access: yesSmall Methods
Ishii S   +7 more
europepmc   +1 more source

Inflammation and mechanical force‐induced bone remodeling

open access: yesPeriodontology 2000, EarlyView.
Abstract Periodontitis arises from imbalanced host–microbe interactions, leading to dysbiosis and destructive inflammation. The host's innate and adaptive immune responses produce pro‐inflammatory mediators that stimulate destructive events, which cause loss of alveolar bone and connective tissue attachment.
Hyeran Helen Jeon   +6 more
wiley   +1 more source

Quantitative dynamic granzyme B PET imaging to characterize novel combination immunotherapy response in preclinical glioblastoma models. [PDF]

open access: yesTheranostics
Gallegos CA   +13 more
europepmc   +1 more source

CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX‐5+ Tumour‐Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Canine cutaneous mast cell tumour (MCT) is the most common skin neoplasm in dogs, with histopathology serving as both the diagnostic and primary prognostic tool. However, identifying reliable biomarkers is essential for improving clinical decision‐making.
Fernanda Ramalho Ramos   +6 more
wiley   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

open access: yesMedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy